HELETIN 100

Indications

• Major depressive disorder
• Obsessive-compulsive disorder
• Panic disorder
• Menopausal symptoms, particularly hot flushes, in women with breast cancer (unlicensed use)

Dosage

Children: Refer to BNF for Children for appropriate dosing.

Adults: Initially 50–100 mg daily, taken in the evening, increased gradually up to a maximum of 300 mg daily if necessary; doses over 150 mg should be given in divided doses. For obsessive-compulsive disorder, start at 10 mg daily, increasing gradually to a maximum of 40 mg daily.

Mechanism of action

Fluvoxamine maleate works by selectively inhibiting the reuptake of serotonin (5-HT) in the brain, increasing the availability of serotonin in the synaptic cleft. This action is believed to contribute to its antidepressant and anxiolytic effects. Additionally, fluvoxamine may have effects on other neurotransmitter systems, including sigma-1 receptors, which can modulate various neurobiological pathways.

Pharmacodynamics

The pharmacodynamic effects of fluvoxamine maleate include increased serotonin levels in the brain, which can lead to improvements in mood, anxiety, and compulsive behaviors. Fluvoxamine has a relatively rapid onset of action, with therapeutic effects often observed within 1-4 weeks of starting treatment. However, it may take longer for some patients to achieve optimal benefits.

Pharmacokinetics

Fluvoxamine is well absorbed from the gastrointestinal tract, with peak plasma concentrations occurring approximately 4-6 hours after oral administration. It is extensively metabolized in the liver, primarily by cytochrome P450 enzymes, and has a half-life of about 15-20 hours. The drug is excreted mainly in urine as metabolites. The presence of hepatic impairment can alter the pharmacokinetics of fluvoxamine, necessitating dose adjustments.

Contra-indications

• Hypersensitivity to fluvoxamine or any of its components
• Severe hepatic impairment
• Concurrent use with monoamine oxidase inhibitors (MAOIs)
• Severe renal impairment

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Somnolence
• Insomnia
• Dry mouth
• Sweating
• Tremor
• Dizziness
• Fatigue
• Sexual dysfunction
• Increased risk of suicidal thoughts and behavior in children, adolescents, and young adults

Interactions

• Increased risk of serotonin syndrome when combined with other serotonergic agents
• Potential interaction with anticoagulants, increasing the risk of bleeding
• May increase plasma levels of other drugs metabolized by cytochrome P450 enzymes

Precautions

• Use with caution in patients with a history of seizure disorders
• Monitor for signs of serotonin syndrome
• Gradual dose reduction is recommended upon discontinuation to avoid withdrawal symptoms
• Caution in patients with a history of bipolar disorder
• Patients with a history of glaucoma should be monitored

Pregnancy

Increased risk of congenital malformations, particularly if used in the first trimester. Use only if potential benefits outweigh risks.

Breast-feeding

Fluvoxamine is present in breast milk, but the amount is generally considered too small to be harmful. Caution is advised.

Storage

Store in a cool, dry place, away from light. Keep out of reach of children.

Formulations

• Fluvoxamine maleate 50 mg tablets
• Fluvoxamine maleate 100 mg tablets
• Fluvoxamine maleate oral suspension

Indications

• Skin disinfection
• Preparation of skin before injections
• Cleansing minor wounds

Dosage

Children: Apply to the skin as required; consult product literature for specific guidance.

Adults: Apply to the skin as required for disinfection.

Mechanism of action

Alcohol exerts its antiseptic effect by denaturing proteins, disrupting cell membranes, and dehydrating microbial cells, leading to cell lysis and death.

Pharmacodynamics

Alcohol has broad-spectrum antimicrobial activity, effective against bacteria, fungi, and viruses. Its efficacy is influenced by concentration, with higher concentrations generally being more effective.

Pharmacokinetics

Alcohol is rapidly absorbed through the skin and mucous membranes. It is metabolized primarily in the liver, with a half-life that varies based on the individual's metabolic rate and the amount consumed.

Contra-indications

• Concomitant use with lithium
• Regular use in neonates
• Patients with severe burns when diathermy has been preceded by application of alcoholic skin disinfectants

Adverse effects

• Eye erythema
• Punctate keratitis
• Cytotoxicity
• Eye discolouration

Interactions

• Increases risk of visual disturbances with antiepileptics
• Increases concentration with methylphenidate
• Increases risk of facial flushing and skin irritation with topical pimecrolimus
• Increases concentration with retinoids
• Increases concentration with acitretin
• Increases risk of facial flushing and skin irritation with topical tacrolimus
• Decreases antidiuretic effect with vasopressin

Precautions

• Avoid regular application to inflamed or broken skin or mucosa
• Avoid broken skin
• Flammable

Pregnancy

Sufficient iodine may be absorbed to affect the fetal thyroid in the second and third trimester.

Breast-feeding

Avoid regular or excessive use.

Storage

Store in a cool, dry place away from heat and direct sunlight.

Formulations

• Betadine 2.5% dry powder spray
• Industrial methylated spirit
• Povidone-Iodine 25 mg per 1 gram

Indications

• Low blood volume
• Hypovolemic shock
• Burns
• Cardiopulmonary bypass

Dosage

Children: Initially 10-20 mL per kilogram. Adjust according to the patient's condition and response, using 3.5-4% solution. Use under specialist supervision to mitigate the risk of fluid overload.

Adults: Dose according to requirements, typically administered intravenously. Consult product literature for specific dosing guidance.

Mechanism of action

Gelatin acts as a plasma expander by increasing the oncotic pressure in the vascular compartment, which helps to retain fluid within the bloodstream and restore circulating blood volume. This mechanism aids in maintaining blood pressure and improving tissue perfusion.

Pharmacodynamics

Gelatin solutions increase blood volume and improve hemodynamic stability in patients experiencing hypovolemic conditions. By drawing water into the vascular space, they help to counteract the effects of low blood volume, such as hypotension and compromised organ perfusion.

Pharmacokinetics

Gelatin is administered intravenously, and its effects can be observed relatively quickly. The half-life and the metabolic clearance depend on the formulation and concentration of the solution. Gelatin is gradually metabolized by macrophages and eliminated by the renal system. Close monitoring of fluid balance is essential, particularly in patients with cardiac or renal impairment.

Contra-indications

• Severe liver disease
• History of circulatory disease
• Severe cardiac disease

Adverse effects

• Fever
• Flushing
• Nausea
• Urticaria
• Rare or very rare shock

Interactions

• Calcium salts

Precautions

• Monitor cardiovascular and respiratory function
• Correct dehydration when administering
• Administer slowly to avoid rapid rise in blood pressure and cardiac failure
• Increased capillary permeability

Pregnancy

Consult product literature for specific guidance regarding use in pregnancy.

Breast-feeding

Consult product literature for specific guidance regarding use in breastfeeding.

Storage

Store at controlled room temperature, protect from light. Refer to product-specific storage instructions.

Formulations

• 5% solution for infusion
• 20% solution for infusion
• Concentrated solution (15-25% protein)
• Isotonic solution (3.5-5% protein)

Indications

• Methemoglobinemia
• Urinary tract infections
• Surgical marking
• Treatment of certain types of cyanide poisoning

Dosage

Children: Refer to the BNF for Children for appropriate pediatric dosing information.

Adults: Refer to the relevant clinical guidelines or the BNF for specific dosing recommendations.

Mechanism of action

Methylene blue acts as a reducing agent, converting methemoglobin back to its functional form, hemoglobin. This is primarily achieved through its action as an electron donor, facilitating the reduction of ferric iron (Fe3+) in hemoglobin to ferrous iron (Fe2+), thereby restoring its oxygen-carrying capacity. It also exhibits antimicrobial properties through its ability to generate reactive oxygen species when exposed to light, which can inhibit bacterial growth.

Pharmacodynamics

The pharmacodynamics of methylene blue involve its role in enhancing oxygen delivery in patients suffering from methemoglobinemia. By converting methemoglobin back to hemoglobin, it effectively increases the amount of hemoglobin available for oxygen transport. The drug also shows effects on the vascular system, where it can induce vasodilation and influence blood pressure.

Pharmacokinetics

Methylene blue is rapidly absorbed after intravenous administration, with peak plasma concentrations occurring within 1 to 3 hours. It is extensively distributed in body tissues and fluids, including the liver, kidneys, and lungs. The drug undergoes hepatic metabolism, primarily through the cytochrome P450 system, and is excreted mainly through urine. The half-life ranges from 5 to 24 hours, depending on the dosage and individual patient factors.

Pregnancy

Consult healthcare provider before use, as safety in pregnancy is not established.

Breast-feeding

Consult healthcare provider before use, as safety during breastfeeding is not established.

Storage

Store in a cool, dry place away from direct sunlight.

Dosage

Children: Refer to specific drug guidelines for dosing information.

Adults: Refer to specific drug guidelines for dosing information.

Mechanism of action

The body operates through various biological mechanisms that involve the interaction of hormones, neurotransmitters, and enzymes. These interactions regulate numerous physiological processes including homeostasis, immune response, and metabolic pathways.

Pharmacodynamics

Pharmacodynamics in the context of the body involves understanding how different substances affect bodily functions. This can include the action of drugs, nutrients, and other chemical agents, which can modify physiological responses through receptor binding, enzyme activity modulation, or ion channel regulation.

Pharmacokinetics

Pharmacokinetics refers to how substances are absorbed, distributed, metabolized, and excreted within the body. Factors such as blood flow, tissue permeability, and enzymatic activity play crucial roles in determining how long a drug remains active in the body, its efficacy, and potential for toxicity.

Pregnancy

Consult healthcare provider before use, as safety during pregnancy may vary based on specific conditions.

Breast-feeding

Consult healthcare provider before use, as safety during breastfeeding may vary based on specific conditions.

Storage

Store in a cool, dry place away from direct sunlight and moisture.

Indications

• Constipation
• Dietary fiber supplementation
• Irritable bowel syndrome
• Diverticular disease
• Weight management

Dosage

Children: Refer to appropriate guidelines for specific dosage; generally taken with adequate fluid intake.

Adults: Refer to appropriate guidelines for specific dosage; generally taken with adequate fluid intake.

Mechanism of action

Cellulose acts primarily as a bulk-forming laxative. It absorbs water in the intestines, which increases stool bulk and stimulates peristalsis, thus facilitating bowel movements. Additionally, cellulose is not digestible by human enzymes, leading to fermentation by gut bacteria, which may enhance gut health and alter gut microbiota composition.

Pharmacodynamics

Cellulose increases stool weight and frequency of bowel movements. It works by retaining water in the intestines, leading to softer stools and improved passage through the gastrointestinal tract. The bulking effect of cellulose can help alleviate constipation and promote overall digestive health. It may also play a role in cholesterol reduction and glycemic control through its effects on digestion and absorption of nutrients.

Pharmacokinetics

Cellulose is not absorbed into the bloodstream due to its indigestible nature. Instead, it passes through the gastrointestinal tract, where it adds bulk to the stool. Its fermentation by colonic bacteria produces short-chain fatty acids, which may have beneficial effects on colon health. The onset of action for cellulose as a laxative can vary but is generally within 24 to 72 hours after ingestion.

Adverse effects

• Bloating
• Flatulence
• Diarrhea
• Abdominal discomfort

Precautions

• Use with caution in patients with a history of gastrointestinal disorders.
• Monitor for potential allergic reactions in sensitive individuals.

Pregnancy

Cellulose is generally considered safe during pregnancy as it is a non-toxic, indigestible fiber.

Breast-feeding

Cellulose is also considered safe during breastfeeding; it is excreted in breast milk in negligible amounts.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Powder
• Capsules
• Tablets
• Granules

Mechanism of action

Dichloromethane induces mammary adenomas in rats through an indirect mechanism involving hyperprolactinaemia, resulting in benign neoplasms. It does not bind to DNA in various tissues, suggesting that its carcinogenic effects are likely mediated through metabolic pathways in the liver. In mice, DCM acts as a hepatic and pulmonary carcinogen, mediated by interaction with DNA through a glutathione (GSH) conjugate produced by the enzyme glutathione S-transferase T1-1 (GST T1-1).

Pharmacodynamics

Dichloromethane exhibits carcinogenic properties, particularly evident in animal studies where exposure leads to liver and lung tumors. The incidence of tumors varies by species, with higher susceptibility observed in mice due to differences in glutathione transferase activity. Its effects on humans are still uncertain, necessitating caution in its handling and use due to potential health risks.

Pharmacokinetics

Dichloromethane is rapidly absorbed through inhalation and dermal exposure, with peak blood concentrations occurring shortly after exposure. It undergoes extensive hepatic metabolism primarily via cytochrome P450 enzymes, leading to the formation of reactive metabolites. The elimination half-life is relatively short, with excretion occurring mainly through the lungs and urine.

Pregnancy

Dichloromethane should be avoided during pregnancy due to its potential carcinogenic effects and lack of safety data in pregnant women.

Breast-feeding

It is not known whether dichloromethane is excreted in human milk, thus it should be used with caution in breastfeeding mothers.

Storage

Store in a cool, dry place away from heat and light. Keep container tightly closed.

Indications

• Alcohol use disorder
• Anxiety disorders
• Sedation
• Muscle relaxation

Dosage

Children: Refer to the BNF for Children for specific dosing guidelines in paediatric populations.

Adults: Refer to the specific BNF guidelines for dosing related to alcohol use disorder and other indications.

Mechanism of action

Ethyl groups serve primarily as substituents in organic chemistry, influencing the properties and reactivity of the parent molecules. In the context of ethanol, which contains an ethyl group, its mechanism of action involves the enhancement of gamma-aminobutyric acid (GABA) receptor activity, leading to increased inhibitory neurotransmission. This results in its sedative, anxiolytic, and muscle relaxant effects.

Pharmacodynamics

The pharmacodynamics of compounds containing the ethyl group, particularly ethanol, include its effects on the central nervous system, where it acts as a depressant. Ethanol enhances the effects of GABA, resulting in sedation, impaired motor function, and decreased anxiety. It can also affect the dopaminergic pathways, leading to the release of dopamine, which contributes to its reinforcing properties.

Pharmacokinetics

Ethanol is rapidly absorbed from the gastrointestinal tract, with peak blood concentrations typically reached within 30 to 90 minutes after consumption. It is metabolized primarily in the liver by alcohol dehydrogenase and aldehyde dehydrogenase, with a first-order elimination kinetics, typically at a rate of 10 to 15 mL of pure alcohol per hour. Ethanol is also known to exhibit a volume of distribution of approximately 0.5 to 0.7 L/kg in adults.

Indications

• Major depressive disorder
• Obsessive-compulsive disorder
• Generalized anxiety disorder
• Social anxiety disorder
• Body dysmorphic disorder

Dosage

Children: Refer to the BNF for Children for paediatric dosing guidelines.

Adults: Refer to the BNF for specific dosing recommendations.

Mechanism of action

Fluvoxamine's exact mechanism of action is not fully elucidated, but it is known to inhibit the reuptake of serotonin at the neuronal membrane's serotonin reuptake pump. This inhibition enhances the activity of serotonin on 5-HT1A autoreceptors. Unlike many other psychotropic agents, fluvoxamine exhibits minimal affinity for adrenergic, cholinergic, dopaminergic, and histaminergic receptors, suggesting a targeted action primarily on serotonin pathways.

Pharmacodynamics

As a potent and selective inhibitor of neuronal serotonin reuptake, fluvoxamine's antidepressant, anti-obsessive-compulsive, and antibulimic effects are linked to its ability to increase serotonin levels in the synaptic cleft. This results in enhanced serotonergic neurotransmission, which is crucial for mood regulation and anxiety reduction. The drug has minimal effects on norepinephrine and dopamine reuptake, further specifying its action among SSRIs.

Pharmacokinetics

Fluvoxamine is absorbed well from the gastrointestinal tract, with peak plasma concentrations typically reached within 3 to 8 hours post-administration. It undergoes extensive hepatic metabolism primarily via cytochrome P450 enzymes, particularly CYP1A2, with an elimination half-life of about 15 to 26 hours. The drug is primarily excreted as metabolites in the urine, and its pharmacokinetics can be significantly affected by drug interactions, particularly with substances that inhibit or induce hepatic enzymes.

Interactions

• fluvoxamine + agomelatine: Severe (increases exposure)
• fluvoxamine + fedratinib: Severe (increases exposure)
• fluvoxamine + melatonin: Severe (increases exposure)
• fluvoxamine + tizanidine: Severe (increases exposure)
• fluvoxamine + antiarrhythmics: Moderate (increases exposure)
• fluvoxamine + propafenone: Moderate (increases exposure)
• fluvoxamine + antipsychotics, second generation: Moderate (increases concentration)
• fluvoxamine + clozapine: Moderate (increases concentration)
• fluvoxamine + olanzapine: Moderate (increases exposure)
• fluvoxamine + benzodiazepines: Moderate (increases exposure)

Pregnancy

Consult relevant guidelines as fluvoxamine should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Fluvoxamine is excreted in breast milk; caution is advised when administered to nursing mothers.

Storage

Store at room temperature, away from moisture and heat.

Dosage

Children: Refer to specific pediatric dosing guidelines based on the identified drug, as 'hard' does not provide sufficient information.

Adults: Refer to specific drug information for dosing guidelines, as 'hard' does not specify a particular medication.

Mechanism of action

The mechanism of action for drugs termed 'hard' must be specified for accurate information, as this phrase does not designate a specific compound. Mechanisms may involve receptor interaction, enzyme inhibition, or modulation of biochemical pathways, depending on the drug in question. For example, opioid analgesics work primarily by binding to mu-opioid receptors in the central nervous system, leading to analgesic effects.

Pharmacodynamics

Pharmacodynamics refers to the effects of a drug on the body and its mechanisms of action. The pharmacodynamics of any drug classified as 'hard' would depend on its specific pharmacological profile, including its efficacy, potency, and the nature of its therapeutic effects. For instance, in the case of opioids, pharmacodynamic effects include pain relief, sedation, and potential respiratory depression.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion (ADME) of a drug. The pharmacokinetics of a substance termed 'hard' would vary significantly based on the specific drug. For many medications, absorption may occur via oral or parenteral routes, distribution may involve binding to plasma proteins, metabolism may occur in the liver, and excretion is typically renal. Each of these parameters is critical for understanding the drug's action and potential side effects.

Pregnancy

Consult a healthcare professional before use, as safety has not been established.

Breast-feeding

Consult a healthcare professional before use, as safety has not been established.

Storage

Store in a cool, dry place, away from direct sunlight.

Indications

• Used as an excipient in pharmaceutical formulations
• Improves solubility and stability of active ingredients
• Facilitates drug absorption

Dosage

Children: Refer to specific product guidelines as hydroxypropyl is typically used as an excipient and not dosed independently.

Adults: Refer to specific product guidelines as hydroxypropyl is typically used as an excipient and not dosed independently.

Mechanism of action

Hydroxypropyl functions primarily as a solubilizing agent, which aids in the dissolution of poorly soluble drugs. It interacts with water and other solvents to improve the dispersion of pharmaceutical compounds, thereby enhancing their bioavailability. Hydroxypropyl may also facilitate the permeability of drug molecules through biological membranes, contributing to their overall efficacy.

Pharmacodynamics

The pharmacodynamics of hydroxypropyl relate to its role in improving the physicochemical properties of drug formulations. By increasing solubility and stability, hydroxypropyl can enhance the absorption of drugs administered via various routes, including oral and topical. Its non-toxic nature allows for safe incorporation into formulations, making it suitable for a wide range of applications.

Pharmacokinetics

The pharmacokinetics of hydroxypropyl have not been extensively studied as it primarily acts as an excipient rather than an active pharmaceutical ingredient. When used in formulations, it is typically not absorbed into systemic circulation in significant amounts, thereby minimizing potential systemic effects. Hydroxypropyl is generally regarded as safe when used in appropriate amounts in drug formulations.

Pregnancy

Hydroxypropyl is not classified for use during pregnancy, and its safety has not been established. Caution is advised.

Breast-feeding

There is limited information on the excretion of hydroxypropyl in human milk. Caution is advised when administering to breastfeeding women.

Storage

Store in a cool, dry place, away from light. Keep out of reach of children.

Dosage

Children: Refer to the specific drug product information for pediatric dosing guidelines.

Adults: Refer to the specific drug product information for dosing guidelines.

Mechanism of action

The mechanism of action for imprinted medications varies widely depending on the active pharmaceutical ingredient contained in the formulation. Generally, the imprint does not influence the pharmacological activity of the drug itself but serves as a means to identify it. For specific drugs, their mechanisms of action can include receptor binding, enzyme inhibition, or modulation of ion channels, among others.

Pharmacodynamics

Pharmacodynamics of imprinted medications will depend on the active ingredients. Typically, the pharmacodynamic profile includes the relationship between drug concentration and its therapeutic effect, which is influenced by factors such as receptor affinity, intrinsic activity, and the drug's therapeutic window. The imprinted form itself does not alter these dynamics but ensures correct identification and administration.

Pharmacokinetics

The pharmacokinetics of imprinted medications are defined by the absorption, distribution, metabolism, and excretion (ADME) of the active ingredients. The imprinting process itself does not influence these pharmacokinetic properties. Factors such as the formulation type, presence of excipients, and patient-specific variables (age, weight, organ function) will determine the pharmacokinetic profile. Generally, pharmacokinetic studies are conducted on the drug as a whole rather than its imprinted form.

Pregnancy

Use with caution. Safety in pregnancy has not been established.

Breast-feeding

Use with caution. Limited data available on excretion in breast milk.

Storage

Store in a cool, dry place, away from light.

Indications

• Disinfection of skin before injections or surgical procedures
• Antiseptic for minor cuts and abrasions
• Cleaning and sanitization of surfaces
• Solvent in pharmaceutical preparations

Dosage

Children: Refer to established guidelines for pediatric use; doses vary based on age and clinical condition.

Adults: For topical use, apply isopropyl alcohol to the affected area as needed. For disinfection, use a concentration of 70% isopropyl alcohol.

Mechanism of action

Isopropyl alcohol exerts its antimicrobial effect primarily by denaturing proteins and dissolving lipids, which disrupts cellular membranes. This action leads to the inactivation of bacteria, viruses, and fungi, making it effective in reducing microbial load on surfaces and skin.

Pharmacodynamics

Isopropyl alcohol demonstrates concentration-dependent activity. At concentrations of 60-90%, it is effective against a broad spectrum of pathogens, including gram-positive and gram-negative bacteria, fungi, and viruses. The mechanism involves dehydration of the microbial cell, leading to cell lysis and death. The rapid evaporation rate of isopropyl alcohol enhances its utility as a topical antiseptic, providing quick action with minimal residue.

Pharmacokinetics

Isopropyl alcohol is readily absorbed through the skin and mucous membranes. When ingested, it is metabolized primarily in the liver to acetone, which is then eliminated through urine. The elimination half-life varies based on the route of exposure and individual metabolism, but generally, isopropyl alcohol is cleared from the body relatively quickly.

Pregnancy

Isopropyl alcohol should be avoided during pregnancy, as it may pose risks to the developing fetus. Its use should be limited to essential applications only, and pregnant individuals should consult healthcare providers before use.

Breast-feeding

Isopropyl alcohol is generally considered safe for topical use during breastfeeding, but ingestion or excessive exposure should be avoided. It is advisable for breastfeeding individuals to consult with healthcare professionals before use.

Storage

Isopropyl alcohol should be stored in a cool, dry place, away from heat sources and open flames. It should be kept in a tightly closed container and out of reach of children.

Formulations

• Isopropyl alcohol 70% solution
• Isopropyl alcohol 91% solution
• Isopropyl alcohol topical wipes

Dosage

Children: For specific paediatric dosing information, please refer to the relevant product monograph or clinical guidelines.

Adults: For specific adult dosing information, please refer to the relevant product monograph or clinical guidelines.

Mechanism of action

The mechanism of action for opaque agents is generally related to their ability to block or scatter light. This is achieved through the use of specific excipients or coating materials that interact with light in such a way as to prevent transmission, thus preserving the integrity of the active pharmaceutical ingredient (API) within the formulation.

Pharmacodynamics

Pharmacodynamics of opaque formulations is primarily focused on the stability of the drug contained within. Light-sensitive drugs can undergo photodegradation, leading to a reduction in efficacy or the formation of harmful degradation products. By using opaque materials, the pharmacodynamic profile of the drug remains intact, ensuring that its therapeutic effects are maintained during storage and use.

Pharmacokinetics

The pharmacokinetics of opaque formulations can vary widely depending on the nature of the drug and its formulation. Generally, the pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion (ADME) are not significantly altered by opacity, but rather focus on how the drug is protected from light. The delivery system must ensure that the drug is released effectively within the body while maintaining its stability against photodegradation during its shelf life.

Pregnancy

The safety of opaque medications during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether opaque medications are excreted in human milk. Caution is advised when administering to breastfeeding women.

Storage

Store in a cool, dry place away from light. Ensure that the container is tightly closed to prevent contamination.

Dosage

Children: Refer to the specific drug's prescribing information for paediatric dosing guidelines.

Adults: Refer to the specific drug's prescribing information for adult dosing guidelines.

Mechanism of action

The mechanism of action would depend on the specific drug referred to by 'size'. Generally, drugs exert their effects through interaction with biological targets such as receptors, enzymes, or ion channels, leading to a physiological response.

Pharmacodynamics

Pharmacodynamics refers to the effects of the drug on the body, including the relationship between drug concentration and effect. This can involve receptor binding, signal transduction, and the resulting biological effects. Specific dynamics would vary based on the drug in question.

Pharmacokinetics

Pharmacokinetics describes the absorption, distribution, metabolism, and excretion (ADME) of a drug. Factors such as bioavailability, volume of distribution, half-life, and clearance would vary significantly based on the specific drug being considered.

Pregnancy

Safety in pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Use with caution, as it is not known whether it is excreted in human milk.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Controlled drug delivery
• Targeted therapy
• Improvement of bioavailability of poorly soluble drugs

Dosage

Children: For pediatric dosing information, refer to guidelines specific to the drug being administered.

Adults: Dosage should be individualized based on the specific drug being delivered and the therapeutic goals. Refer to specific drug guidelines for accurate dosing information.

Mechanism of action

The mechanism of action of spheres primarily involves the encapsulation of active pharmaceutical ingredients (APIs) within a spherical matrix. Upon administration, the spheres can release the drug through diffusion, degradation of the matrix, or a combination of both processes. This allows for sustained or targeted delivery of the drug to specific sites within the body, improving treatment efficacy.

Pharmacodynamics

The pharmacodynamic properties of spheres depend on the drug they encapsulate and the design of the delivery system. Generally, spheres can enhance drug solubility and stability, allowing for improved bioavailability. The release profile can be tailored to achieve desired therapeutic concentrations over time, which can lead to improved patient adherence and reduced toxicity.

Pharmacokinetics

Pharmacokinetics of spheres is influenced by factors such as the size of the spheres, the material used for their construction, and the method of drug release. After administration, the spheres can be distributed through the bloodstream, and their release rates can vary based on their composition and the physiological conditions of the body. The elimination of the spheres and the encapsulated drug typically occurs via metabolic pathways and renal or hepatic clearance.

Pregnancy

Safety during pregnancy has not been established. Use only if potential benefits justify the risks to the fetus.

Breast-feeding

It is unknown whether spheres are excreted in human milk. Caution should be exercised when administered to a nursing woman.

Storage

Store in a cool, dry place away from direct sunlight and moisture.

Indications

• Providing energy in dietary supplementation
• Enhancing flavor in food products
• Replacement of carbohydrates in certain medical nutrition therapies

Dosage

Children: Refer to general dietary guidelines for carbohydrate intake in children. No specific dosing guidelines provided.

Adults: Refer to general dietary guidelines for carbohydrate intake. No specific dosing guidelines provided.

Mechanism of action

Sugar is metabolized in the body to provide energy. Upon ingestion, sucrose is broken down by the enzyme sucrase into its constituent monosaccharides, glucose and fructose, which are then absorbed into the bloodstream. These monosaccharides can be utilized by cells for energy or stored as glycogen in the liver and muscles.

Pharmacodynamics

As a simple carbohydrate, sugar elevates blood glucose levels rapidly after consumption, leading to increased insulin secretion from the pancreas. This insulin facilitates the uptake of glucose by tissues, promoting energy production. The rapid increase in blood sugar can provide quick energy but may also lead to potential negative effects on metabolism and weight if consumed in excess.

Pharmacokinetics

After oral administration, sugar is quickly hydrolyzed in the gastrointestinal tract. Peak plasma glucose concentrations typically occur within 30 minutes to 2 hours post-ingestion, depending on the amount consumed and individual metabolism. The half-life of glucose in the bloodstream is relatively short, as it is rapidly taken up by tissues or converted into glycogen.

Pregnancy

Sugar is generally considered safe for use during pregnancy, but excessive intake should be avoided to prevent gestational diabetes and excessive weight gain.

Breast-feeding

Sugar is safe during breastfeeding; however, excessive consumption should be avoided.

Storage

Store in a cool, dry place, away from moisture and direct sunlight.

Formulations

• Granulated sugar
• Brown sugar
• Powdered sugar
• Liquid sugar

Indications

• Used as an excipient in drug formulations
• Pleurodesis for the management of recurrent pleural effusions

Dosage

Children: Refer to specific guidelines for paediatric use, as dosing may differ based on age and clinical condition.

Adults: Refer to specific guidelines for the appropriate dosage in pleurodesis and other applications, as it may vary based on clinical context.

Mechanism of action

Talc exhibits very good absorptive properties, allowing it to absorb moisture and other substances effectively. This characteristic is particularly useful in pharmaceutical formulations, where it may enhance the stability and texture of the drug product.

Pharmacodynamics

Talc's primary pharmacodynamic effect is its ability to act as an inert filler and bulking agent in pharmaceutical preparations. It does not have any intrinsic pharmacological activity but serves to improve the physical properties of formulations, such as flowability and compressibility.

Pharmacokinetics

Talc is not absorbed systemically when used as an excipient or in medical procedures. Its effects are local, and it remains in the site of application, where it functions primarily as a mechanical agent. The pharmacokinetics of talc in the context of its use in pleurodesis involves its ability to promote adhesion of the pleural surfaces, thereby preventing fluid accumulation.

Pregnancy

Talc is classified as a substance with minimal systemic absorption, but safety during pregnancy has not been well established. Consult relevant guidelines.

Breast-feeding

Talc is not expected to be absorbed in significant amounts; however, caution is advised and consult guidelines.

Storage

Store in a cool, dry place, away from direct sunlight.

Dosage

Children: Refer to specific guidelines or pharmacological texts, as no established clinical dosing is available.

Adults: Refer to specific guidelines or pharmacological texts, as no established clinical dosing is available.

Mechanism of action

Triethyl functions as an alkylating agent, introducing alkyl groups into various substrates, which can lead to the modification of nucleic acids and proteins. This mechanism can result in the disruption of normal cellular processes, including inhibition of DNA replication and transcription, ultimately leading to cell death in susceptible cells. Its reactivity is primarily due to the presence of multiple ethyl groups, which can interact with nucleophilic sites in biological molecules.

Pharmacodynamics

The pharmacodynamics of triethyl are characterized by its ability to form covalent bonds with nucleophilic sites in biomolecules, influencing cellular functions and integrity. The modulation of DNA and protein function can lead to cytotoxic effects, particularly in rapidly dividing cells. Its effects may be dose-dependent, with higher concentrations resulting in increased toxicity and potential side effects.

Pharmacokinetics

Triethyl's pharmacokinetics are not well-studied in a clinical context, as it is primarily utilized in chemical processing rather than therapeutic applications. However, when considering alkylating agents in general, they may exhibit variable absorption, distribution, metabolism, and excretion depending on their chemical structure and the route of exposure. Following administration, such compounds can accumulate in tissues, particularly in the liver and kidneys, and may undergo metabolic transformation before excretion. Due to its reactive nature, triethyl can also pose risks of toxicity and adverse effects.

Adverse effects

• Nausea
• Vomiting
• Dizziness
• Headache
• Respiratory depression

Precautions

• Use with caution in patients with a history of respiratory issues
• Monitor liver function tests due to potential hepatotoxicity

Pregnancy

Triethyl is not recommended during pregnancy due to potential risks to the fetus.

Breast-feeding

Caution is advised as it is not known if triethyl is excreted in breast milk.

Storage

Store in a cool, dry place away from light and moisture.

Pregnancy

No specific data available, consult a healthcare professional.

Breast-feeding

No specific data available, consult a healthcare professional.

Storage

Store in a cool, dry place away from light.

Mechanism of action

Ethanol affects the brain’s neurons in several ways. It alters their membranes as well as their ion channels, enzymes, and receptors. Alcohol also binds directly to the receptors for acetylcholine, serotonin, GABA, and the NMDA receptors for glutamate. The sedative effects of ethanol are mediated through binding to GABA receptors and glycine receptors (alpha 1 and alpha 2 subunits). It also inhibits NMDA receptor functioning. In its role as an anti-infective, ethanol acts as an osmolyte or dehydrating agent that disrupts the osmotic balance across cell membranes. ... Ethanol is known to affect a large number of membrane proteins that participate in signaling pathways such as neurotransmitter receptors, enzymes, and ion channels, and there is extensive evidence that ethanol interacts with a variety of neurotransmitters. The major actions of ethanol involve enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) at GABAa receptors and blockade of the N-methyl-D-aspartate (NMDA) subtype of glutamate, an excitatory amine acid (EAA) receptor. Animal studies indicate that the acute effects of ethanol result from competitive inhibition of glycine binding to NMDA receptor and disruption of glutamatergic neurotransmission by inhibiting the response of the NMDA receptor. Persistent glycine antagonism and attenuation of glutamatergic neurotransmission by chronic ethanol exposure results in tolerance to ethanol by enhancing EAA neurotransmission and NMDA receptor upregulation. The latter appears to involve selective increases in NMDA R2B subunit concentrations and other molecular changes in specific brain loci. The abrupt withdrawal of ethanol thus produces a hyperexcitable state that leads to the ethanol withdrawal syndrome and excitotoxic neuronal death. GABA-mediated inhibition, which normally acts to limit excitation, is eliminated during ethanol withdrawal syndrome and further intensifies this excitation. In addition, NMDA receptors function to inhibit the release of dopamine in the nucleus accumbens and mesolimbic structures, which modulate the reinforcing action of addictive xenobiotics such as ethanol. By inhibiting NMDA receptor activity, ethanol could increase dopamine release from the nucleus accumbens and ventral tegmental area and could thus create dependence. Chronic ethanol administration also results in tolerance, dependence, and an ethanol withdrawal syndrome, mediated, in part, by desensitization and or downregulation of GABAa receptors. The development of alcoholic ketoacidosis (AKA) requires that a combination of physical and physiologic events occur. The normal response to starvation and depletion of hepatic glycogen stores is for amino acids to be converted to pyruvate. Pyruvate can serve as a substrate for gluconeogenesis, be converted to acetyl-CoA, which can enter the Krebs cycle or can be utilized in various biosynthetic pathways (eg, fatty acid, ketone bodies, cholesterol, and acetylcholine) ... Ethanol metabolism generates NADH, resulting in an excess of reducing potential. This high redox state favors the conversion of pyruvate to lactate, diverting pyruvate from being a substrate for gluconeogenesis. To compensate for the lack of normal metabolic substrates, the body mobilizes fat from adipose tissue and increased fatty acid metabolism as an alternative source of energy. This response is mediated by a decrease in insulin and an increased secretion of glucagon, catecholamines, growth hormone, and cortisol. Fatty acid metabolism results in the formation of acetyl-CoA and it combines with the excess acetate that is generated from ethanol metabolism to form acetoacetate. Most of the acetoacetate is reduced to beta-hydroxybutyrate due to the excess reducing potential or high redox state of the cell. Volume depletion interferes with the renal elimination of acetoacetate and beta-hydroxybutyrate, and contributes to the acidosis. An elevated lactate concentration may result from shunting from pyruvate or

Pharmacodynamics

Alcohol produces injury to cells by dehydration and precipitation of the cytoplasm or protoplasm. This accounts for its bacteriocidal and antifungal action. When alcohol is injected in close proximity to nerve tissues, it produces neuritis and nerve degeneration (neurolysis). Ninety to 98% of ethanol that enters the body is completely oxidized. Ethanol is also used as a cosolvent to dissolve many insoluble drugs and to serve as a mild sedative in some medicinal formulations. Ethanol also binds to GABA, glycine, NMDA receptors and modulates their effects. Ethanol is also metabolised by the hepatic enzyme alcohol dehydrogenase.

Mechanism of action

The mechanism by which methylene chloride induces mammary adenomas in the rat is important for human hazard assessment. Female Sprague- Dawley rats receiving methylene chloride have a high blood level of prolactin. In common with the response to other agents which act via hyperprolactinaemia, the methylene chloride-induced response is of benign neoplasms only. There is no evidence for the binding of methylene chloride to the DNA of other tissues and hence it seems unlikely that it will bind to mammary tissue when the primary site of metabolism is the liver. It seems most likely, therefore, that the increased incidence of mammary adenomas is the result of an indirect mechanism operating via hyperprolactinaemia. Dichloromethane (DCM) is a hepatic and pulmonary carcinogen in mice exposed to high doses by inhalation. It has been shown previously that the incidence of liver and lung tumors does not increase in rats or hamsters exposed to the dihaloalkane under conditions similar to those that produced tumors in mice. The biological consequences of DCM exposure to humans is therefore uncertain. The carcinogenic effects of DCM in the mouse are caused by the interaction with DNA of a glutathione (GSH) conjugate that is produced by the class theta glutathione S-transferase T1-1 (GST T1-1). The species specificity is thought to be due to the greater amount of transferase activity in mouse target organs and specific nuclear localization of GST T1-1 in target cells. This paper directly compares the relative capacity and locality of DCM activation in mouse and human tissues. The results show that mouse GST T1-1 is more efficient in catalyzing the conjugation of DCM with GSH than the orthologous human enzyme. In addition, the mouse expresses higher levels of the transferase than humans in hepatic tissue. Histochemical analysis confirmed the presence of GST T1-1 in the nucleus of mouse liver cells. However, in human liver GST T1-1 was detected in bile duct epithelial cells and hepatocyte nuclei but was also present in the cytoplasm. Taking this information into account, it is unlikely that humans have a sufficiently high capacity to activate DCM for this compound to be considered to represent a carcinogenic risk. Dichloromethane (DCM) is considered a probable human carcinogen. Laboratory studies have shown an increased incidence of lung and liver cancer in mice but not in rats or hamsters. Despite the correlation between metabolism of DCM by the glutathione-S-transferase (GST) pathway and the occurrence of tumors in different species, the mechanism of tumor induction by DCM metabolites produced through the GST pathway remains unclear. In this study a V79 cell line stably transfected with the murine GST theta 1 gene (mGSTT1) was compared to the parent cell line (MZ) to determine how the construct affects DCM metabolism and the sensitivity of the cell line to DNA damage and cytotoxicity. V79 cells were treated with DCM (2.5-10mM) or formaldehyde (150-600muM) for 2hr. Also, formaldehyde produced by V79 cytosol metabolism of DCM was measured spectrophotometrically. DNA damage and DNA-protein crosslinks were measured by the standard and proteinase K-modified alkaline single cell gel electrophoresis (SCG) assays. Cytotoxicity was assessed by trypan blue stain exclusion, the Live/Dead((R)) cell viability/cytotoxicity kit for animal cells, and the neutral red assay. After DCM treatment a significant concentration-dependent increase in tail moment in the V79 MZ cells was observed compared to a significant concentration-dependent decrease in tail moment in the V79 mGSTT1 cells. Post-incubation with proteinase K significantly increased DNA migrations in DCM-treated V79 mGSTT1 cells. DCM formed significantly higher levels of formaldehyde in the cytosol of the V79 mGSTT1 cells than in the cytosol of the V79 MZ cells. Results using the cytotoxicity assays were comparable using the trypan blue and Live/Dead((R)) assays, neither showing a difference in resp

Mechanism of action

The exact mechanism of action of fluvoxamine has not been fully determined, but appears to be linked to its inhibition of CNS neuronal uptake of serotonin. Fluvoxamine blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT_1A autoreceptors. Studies have also demonstrated that fluvoxamine has virtually no affinity for α₁- or α₂-adrenergic, β-adrenergic, muscarinic, dopamine D₂, histamine H₁, GABA-benzodiazepine, opiate, 5-HT₁, or 5-HT₂ receptors, despite having an affinity for binding to σ1 receptors.

Pharmacodynamics

Fluvoxamine, an aralkylketone-derivative agent, is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs) that differs structurally from other SSRIs. It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of Fluvoxamine are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. <i>In vitro</i> studies show that Fluvoxamine is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Moreover, apart from binding to σ1 receptors, fluvoxamine has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT_1A, 5HT_1B, 5HT₂), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. Furthermore, some studies have demonstrated that the chronic administration of Fluvoxamine was found to downregulate brain norepinephrine receptors (as has been observed with other drugs effective in the treatment of major depressive disorder), while others suggest the opposite.

Mechanism of action

It has very good absorptive properties.